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Background. Diagnosis and treatment of sexually transmitted infections (STIs) is a public health priority,
particularly in regions where the incidence of human immunodeficiency virus (HIV) infection is high. In most
developing countries, STIs are managed syndromically. We assessed the adequacy of syndromic diagnosis of STIs,
compared with laboratory diagnosis of STIs, and evaluated the association between STI diagnosis and the risk of
HIV acquisition in a cohort of high-risk women.
Methods. HIV-uninfected high-risk women (n = 242) were followed for 24 months. Symptoms of STIs were
recorded, and laboratory diagnosis of common STI pathogens was conducted every 6 months. Forty-two cytokines
were measured by Luminex in cervicovaginal lavage specimens at enrollment. Human immunodeficiency virus
type 1 (HIV-1) infection was evaluated monthly.
Results. Only 12.3% of women (25 of 204) who had a laboratory-diagnosed, discharge-causing STI had clini-
cally evident discharge. Vaginal discharge was thus a poor predictor of laboratory-diagnosed STIs (sensitivity,
12.3%; specificity, 93.8%). Cervicovaginal cytokine concentrations did not differ between women with asymptom-
atic STIs and those with symptomatic STIs and were elevated in women with asymptomatic STIs, compared with
women with no STIs or bacterial vaginosis. Although laboratory-diagnosed STIs were associated with increased
risk of HIV infection (hazard ratio, 3.3 [95% confidence interval, 1.5–7.2)], clinical symptoms were not.
Conclusions. Syndromic STI diagnosis dependent on vaginal discharge was poorly predictive of laboratory-
diagnosed STI. Laboratory-diagnosed STIs were associated with increased susceptibility to HIV acquisition, while
vaginal discharge was not.
Sexually transmitted infections (STIs) impose a major
health burden, particularly in developing countries
such as South Africa, where the prevalence of
human immunodeficiency virus type 1 (HIV-1) in-
fection is high [1, 2]. In South Africa, most new
HIV infections are sexually transmitted, and women
are at higher risk of infection than men [3]. As STIs
are associated with increased susceptibility to HIV in-
fection, they have likely played a central role in facili-
tating the spread of HIV [4–11]. STI management is
thus a key issue in preventing HIV infection in coun-
tries where both HIV infection and other STIs are
prevalent.
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Developing countries such as South Africa manage most
STIs syndromically, on the basis of signs and symptoms [12].
Etiological diagnosis is expensive and time-consuming and re-
quires laboratory equipment and suitably trained staff, whereas
syndromic management is easily implemented and inexpensive,
with immediate treatment available [12, 13]. However, because
the STI syndromes used for diagnosis are nonspecific and
because a large proportion of STIs are asymptomatic, under-
treatment, and sometimes overtreatment, are pervasive [14–18].
In South Africa, asymptomatic infections occur in almost 50%
of STI-infected women who do not seek care and therefore
remain untreated [19]. Untreated STIs are associated with sig-
nificant direct sequelae, including pelvic inflammatory disease
(PID), ectopic pregnancy, and tubal factor infertility [20]. On
the other hand, a significant number of women with conditions
such as vaginal discharge resulting from a derangement of
normal vaginal flora may be treated for STIs that they do not
have. The costs associated with overtreatment include the finan-
cial burden of supplying medicines, the potential development
of antimicrobial resistance, and the social cost of misdiagnosis.
Several studies have investigated the influence of different
strategies for STI management on the risk of HIV infection.
Population-wide treatment of bacterial infections or therapy
for herpes simplex virus 2 (HSV-2) was found to be ineffec-
tive at reducing HIV infection [21–25]. Two of 3 syndromic
management interventions found no difference in HIV
acquisition [26–29], suggesting that asymptomatic infections
may play a role. In addition to causing visible clinical
symptoms, certain STIs may be associated with subclinical
manifestations, including elevated genital tract inflammatory
cytokine responses [14, 30]. Although a direct association
between genital tract inflammatory cytokines and suscepti-
bility to HIV infection has not yet been demonstrated,
previous studies have suggested that inflammatory cytokines
may directly upregulate HIV replication in the genital
tract by activating nuclear factor κB and by recruiting and
activating various immune cells which act as targets for
HIV infection [31–34]. Additionally, proinflammatory cyto-
kines such as tumor necrosis factor α (TNF-α) may facilitate
HIV infection by disrupting tight junctions between epitheli-
al cells, reducing the integrity of this barrier [35–37].
The aim of this study was to establish the prevalence and
incidence of STIs in a longitudinal cohort of HIV-uninfected
women with multiple sexual partners in South Africa. The ad-
equacy of syndromic management was evaluated by compar-
ing clinical signs and symptoms to laboratory diagnosis of
STIs. Inflammatory cytokine concentrations in cervicovaginal
lavage (CVL) specimens were measured to determine whether
women who had asymptomatic laboratory-diagnosed STIs
also had subclinical inflammation that may facilitate HIV in-
fection. Last, associations between STIs, cytokine concentra-
tions, and HIV acquisition were investigated.
MATERIALS AND METHODS
Study Design
A total of 775 high-risk women were screened for HIV infec-
tion, and 245 HIV-uninfected women were enrolled into a pro-
spective observational cohort study, the CAPRISA 002 Acute
HIV Infection study, which was conducted in Durban, South
Africa [38]. Participants attended the clinic monthly for risk-
reduction counseling, condom provision, and HIV testing.
STIs were assessed at enrollment and every 6 months thereaf-
ter. Acute HIV infection was diagnosed by detection of HIV
RNA in the absence of HIV antibodies or on the basis of a
reactive HIV antibody test within 5 months of a previously
known negative antibody result. Laboratory diagnosis of STIs
was conducted at enrollment and every 6 months thereafter.
Ethics approval for the study was obtained from the University
of KwaZulu-Natal and the University of Cape Town. Written
informed consent was obtained from all participants.
Laboratory Diagnosis of STIs
A gynecological examination, including a speculum examination
using an unlubricated sterile bivalve speculum, was performed
at enrollment and every 6 months thereafter to visualize any cer-
vical changes, and appropriate samples were collected from any
suspicious lesions. Two vulvovaginal swab specimens were col-
lected from the posterior fornices and lateral vaginal walls at
each examination. Blood specimens were collected for serologi-
cal testing for Treponema pallidum and HSV-2. All specimens
were transported to the diagnostic laboratory (Medical Microbi-
ology Laboratory, University of KwaZulu-Natal) within 1 hour
of collection for same-day processing. One vulvovaginal swab
specimen was rolled onto a glass slide for Gram staining for di-
agnosis of bacterial vaginosis, using Nugents criteria. The
second swab specimen was used to extract DNA for detection of
Neisseria gonorrhoeae and Chlamydia trachomatis, using the
BDProbe Tec ET polymerase chain reaction (PCR) assay
(Becton Dickinson Microbiology Systems, United States), and
for detection of Trichomonas vaginalis, Mycoplasma genitalium,
and HSV-2, using an in-house PCR assay [39].
Genital ulcers were diagnosed as previously described, on
the basis of PCR testing for T. pallidum, Haemophilus ducreyi,
C. trachomatis (lymphogranuloma venereum types), and
HSV-2 [40]. An impression slide of ulcers for microscopy was
collected for the diagnosis of Calymmatobacterium granulo-
matis, if suspected clinically. HerpeSelect-1 and HerpeSelect-2
enzyme immunoassays were used to confirm genital herpes di-
agnosis and to identify asymptomatic carriers. Syphilis screen-
ing was done using the Becton Dickinson Macro-Vue RPR
(rapid plasma reagin [RPR]) card test, and positive reactions
were confirmed by the T. pallidum hemagglutination test
(Omega ImmuTrep TPHA test). The RPR test was done on
serum samples that were undiluted or diluted at ratio of 1:8.










Collection of CVL Specimens and Cytokine Measurements
CVL samples for cytokine measurements were collected from
study participants at enrollment into the study, as previously
described [41]. Sterile normal saline (10 mL) was used to re-
peatedly bathe the cervix. The fluid was allowed to pool in the
posterior fornix, where it was then aspirated into a plastic bulb
pipette. Samples were centrifuged, and the supernatant was
stored at −80°C. CVL samples were not collected from men-
struating participants, for whom sampling was postponed to
the following week. CVL samples for cytokine analysis were
available for a subset of 227 of 242 women who were included
in this study, of whom 66 had ≥1 STI (excluding bacterial
vaginosis and HSV-2 serology findings). Prior to cytokine
measurements, CVL samples were prefiltered by centrifugation
using 0.2 μm cellulose acetate filters (Sigma, United States).
Concentrations of epidermal growth factor, eotaxin/CCL11,
fibroblast growth factor 2, fms-like tyrosine kinase 3 ligand
(Flt-3L), fractalkine/CX3CL1, granulocyte colony-stimulating
factor (CSF), granulocyte macrophage CSF, growth related
oncogene family (CXCL1-CXCL3), interferon α (IFN-α), in-
terferon γ (IFN-γ), interleukin 1α (IL-1α), interleukin 1β
(IL-1β), interleukin 1 receptor antagonist, interleukin 2 (IL-2),
interleukin 3, interleukin 4, interleukin 5, interleukin 6 (IL-6),
interleukin 7, interleukin 8 (IL-8)/CXCL8, interleukin 9, inter-
leukin 10, interleukin 12p40, interleukin 12p70 (IL-12p70),
interleukin 13 (IL-13), interleukin 15, interleukin 17 (IL-17),
IFN-γ–induced protein 10/CXCL10, monocyte chemotactic
protein 1/CCL2, monocyte chemotactic protein 3/CCL7, mac-
rophage-derived chemokine/CCL22, macrophage inflammato-
ry protein 1α/CCL3, macrophage inflammatory protein 1β/
CCL4, platelet-derived growth factor AA, platelet-derived
growth factor AB/BB, RANTES/CCL5, soluble CD40 ligand
(sCD40L), soluble IL-2 receptor α, transforming growth factor
α, tumor necrosis factor α (TNF-α), tumor necrosis factor β
(TNF-β), and vascular endothelial growth factor (VEGF) were
measured using Human Cytokine LINCOplex kits (LINCO
Research, MO), according to the manufacturer’s protocol. The
sensitivity of these kits ranged from 0.01 and 18.3 pg/mL for
each of the 42 cytokines measured. Data were collected using
a Bio-Plex Suspension Array Reader (Bio-Rad Laboratories),
and a 5-parameter logistic regression formula was used to cal-
culate sample concentrations from the standard curves. Data
were analyzed using BIO-plex manager software (version 4).
Cytokine levels that were below the lower limit of detection of
the assay were reported as the midpoint between the lowest
concentration measured and zero.
Statistical Methods
Data was analyzed using SAS, version 9.2 (SAS Institute, Cary,
NC), GraphPad Prism version 5 (GraphPad Software, San
Diego, CA), and STATA (StataCorp, TX). Demographic and
baseline behavioral characteristics are described overall and by
STI and genital symptom profile at enrollment. The Fisher
exact test and the Kruskal–Wallis test were used to compare
characteristics between the groups. STI incidence was calculat-
ed during follow-up for participants who were STI negative at
baseline or for whom resolution of a previous infection
allowed detection of a newly acquired STI. Sensitivity, specifi-
city and positive and negative predictive values were calculated
for STI diagnosis by discharge and genital ulcers, using labora-
tory results as the true diagnosis. A Mann–Whitney U test was
used to compare cytokine concentrations at enrollment in un-
matched women with asymptomatic and symptomatic STIs
and women with none of the assessed STIs. Hierarchical clus-
tering was used to cluster women according to the relatedness
of their cytokine expression profiles (Qlucore Omics Explorer).
Principal component analysis (PCA) was used to simplify the
data set and generate new variables (component estimates),
which are representative of the unique and common variance
of each of the included cytokines. P values were adjusted using
a false discovery rate step-down procedure in order to reduce
false-positive results when multiple comparisons were made
[42]. The hazard ratios (HRs) for HIV infection were calculated
using proportional hazards regression models with STIs as
time-varying covariates. A multivariate proportional hazard
model was also fitted, with adjustment for all laboratory-
diagnosed STIs, clinical symptoms, and demographic and
behavioral factors. Only STI infections diagnosed prior to the
estimated date of HIV infection were included in the models
predicting HIV infection. Demographic and behavioral factors
associated with HIV risk will, however, be explored in more
detail in a separate analysis. Participants lost to follow-up were
censored at the last contact visit, while all other participants
were censored at the time of the last clinic visit.
RESULTS
High Prevalence and Incidence of STIs in this Cohort of High
Risk Women
A total of 245 high-risk HIV-uninfected women were enrolled
into this study and followed for up to 24 months. Of these,
242 were included in the STI analysis, as 3 participants did
not have preinfection data available. At enrollment, 57.0% of
women reported having multiple “stable” partners, while
35.7% had 1 stable partner or were married. However, most
women (95.0%) reported having had >1 casual sex partner
within the last 3 months, and 78.8% were self-identified
female sex workers (Table 1) [38]. The prevalence of laboratory-
diagnosed STIs at enrollment was high: 20.3% had T. vagina-
lis, 5.4% had N. gonorrhoeae, 4.2% had C. trachomatis, 1.2%
had M. genitalium, and 3.7% were HSV-2 positive on PCR.
Of these, 25.3% of women received a diagnosis one of 1 STI,
and 5.8% received a diagnosis of ≥2 STIs. HSV-2 antibodies
were detected in 86.0% of the women, while the prevalence of










bacterial vaginosis was 52.7% (Table 2). During the study
period, the incidence of any STI (excluding bacterial vaginosis
and HSV-2 serology findings) was 26.7 cases per 100 person-
years, and the incidences of T. vaginalis, N. gonorrhoeae,
C. trachomatis, M. genitalium, and T. pallidum were 14.7, 3.3,
4.8, 3.8, and 2.1 cases per 100 person-years, respectively.
Most Women With Laboratory-Diagnosed STIs Were
Asymptomatic
Occurrence of genital ulcer disease and abnormal vaginal dis-
charge was compared to laboratory diagnosis of STIs. Only 3
participants presented with genital ulcers during the follow-up
period, and none presented at enrollment. Each of these
women tested positive for HSV-2 IgG antibodies prior to the
ulcer episode. However, only one of these women tested posi-
tive for HSV-2 by PCR after receiving an etiological diagnosis.
The other 2 women were negative for all of the ulcer-causing
organisms assessed (T. pallidum, H. ducreyi, C. trachomatis,
HSV-2, and C. granulomatis).
At enrollment, 15.3% of women presented with vaginal dis-
charge, while only 1.5% and 4.8% reported vaginal discharge
at their 6- and 12-month study visits, respectively (Table 2).
Contrary to this, at enrollment 27.5% of women tested positive
for a vaginal discharge–associated STI (T. vaginalis, N. gonor-
rhoeae, M. genitalium, or C. trachomatis), with 18.5% and
23.9% testing positive at their 6- and 12-month visits,
respectively.
Overall, only 34.3% of vaginal discharge incidents were
accompanied by a positive laboratory test for ≥1 discharge-
associated STI (Table 3). Meanwhile, a total of 87.7%
laboratory-diagnosed STIs (discharge associated) had no ac-
companying clinical symptoms. Assuming laboratory testing
of the above STIs to be the reference standard, the presence of
discharge for screening had a sensitivity of 12.3%, a specificity
of 93.8%, a positive predictive value of 34.3%, and a negative
predictive value of 80.2%. Therefore, only 12.3% of women
with a confirmed laboratory-diagnosed STI would have been
appropriately treated using vaginal discharge as an indicator
for syndromic treatment.
Asymptomatic Laboratory-Diagnosed STIs Were Associated
With Elevated Genital Tract Inflammatory Cytokine
Concentrations
The concentrations of 42 cytokines were measured in CVL
samples from study participants in order to determine
whether women who had asymptomatic STIs also had











(n = 12) P
Education
Primary school 60 (24.5) 18 (21.7) 14 (21.5) 2 (16.7) .7827
Secondary school to grade 10 84 (34.3) 29 (34.9) 28 (43.1) 6 (50.0)
Secondary school grade 11 and higher 101 (41.2) 36 (43.4) 23 (35.4) 4 (33.3)
Marital status
Single 18 (7.4) 9 (11.0) 6 (9.2) 0 (0.0) .1336
Stable partner/married 87 (35.7) 32 (39.0) 22 (33.9) 1 (8.3)
Many partners 139 (57.0) 41 (50.0) 37 (56.9) 11 (91.7)
No. of casual sex partners in last 3 mo
0 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) .0475
1 12 (5.0) 5 (6.2) 2 (3.1) 0 (0.0)
2–5 205 (85.4) 73 (90.1) 51 (79.7) 10 (83.3)
>5 23 (9.6) 3 (3.7) 11 (17.2) 2 (16.7)
No. of steady sexual partners in last 3 mo
0 8 (3.3) 1 (1.2) 5 (7.8) 0 (0.0) .0717
1 157 (65.2) 59 (72.0) 35 (54.7) 10 (83.3)
2–5 70 (29.1) 20 (24.4) 22 (34.4) 1 (8.3)
>5 6 (2.5) 2 (2.4) 2 (3.1) 1 (8.3)
No. who reported condom use at last sex act 144 (58.8) 54 (65.1) 36 (55.4) 8 (66.7) .4390
Mean age in years (SD) 34.2 (10.5) 34.6 (9.7) 34.2 (11.5) 31.6 (8.0) .5974
Mean age of sexual debut in years (SD) 17.0 (2.4) 17.1 (2.4) 16.4 (1.9) 16.4 (2.6) .2830
Abbreviations: BV, bacterial vaginosis; STI, sexually transmitted infection.










subclinical genital inflammation. Cytokine concentrations in
CVL specimens were compared in (1) women who tested neg-
ative for all assessed STIs and bacterial vaginosis, (2) women
who had vaginal discharge and tested positive for ≥1 STI
(excluding bacterial vaginosis and HSV-2 serology findings),
and (3) women who had no clinical symptoms but tested
positive for ≥1 STI (excluding bacterial vaginosis and HSV-2
serology findings; Figure 1A). The concentrations of IL-1α,
Table 2. Prevalence and Incidence of Laboratory-Diagnosed Sexually Transmitted Infections (STIs) and Clinical Symptoms
Prevalence, % (Proportion)
Incidence, Cases/100 py (95% CI)Variable Enrollment (n = 242) 6 mo (n = 260) 12 mo (n = 189)
Laboratory diagnosis
HSV-2 serology 86.0 (208/242) 90.1 (183/203) 91.0 (171/188) 26.0 (11.2–51.2)
HSV-2 PCR 3.7 (9/241) 1.5 (3/205) 2.2 (4/185) 4.1 (2.2–6.9)
T. pallidum 2.9 (7/242) 3.0 (6/202) 1.6 (3/184) 2.1 (.8–4.3)
BV 52.7 (127/241) 46.8 (96/205) 42.9 (79/184) 50.5 (40.9–61.6)
T. vaginalis 20.3 (49/241) 13.2 (27/205) 17.3 (32/185) 14.7 (10.7–19.7)
N. gonorrhoeae 5.4 (13/240) 2.0 (4/205) 2.2 (4/184) 3.3 (1.6–5.8)
C. trachomatis 4.2 (10/240) 4.4 (9/205) 3.3 (6/184) 4.8 (2.7–7.7)
M. genitalium 1.2 (3/241) 1.5 (3/205) 3.8 (7/185) 3.8 (2.0–6.5)
Any STI (excluding BV and HSV-2 serology) 31.3 (75/240) 21.7 (44/203) 27.5 (50/182) 26.7 (20.8–33.7)
1 25.3 (61/241) 17.6 (36/205) 24.3 (45/185) …
>1 5.8 (14/241) 3.9 (8/205) 2.7 (5/185) …
Clinical diagnosis
Vaginal discharge 15.3 (37/242) 1.5 (3/203) 4.8 (9/189) 14.2 (10.6–18.5)
Abbreviations: BV, bacterial vaginosis; CI, confidence interval; C. trachomatis, Chlamydia trachomatis; HSV-2, herpes simplex virus 2; Mycoplasma genitalium,
M. genitalium; N. gonorrhoeae, Neisseria gonorrhoeae; PCR, polymerase chain reaction; py, person-years; T. pallidum, Treponema pallidum; T. vaginalis,
Trichomonas vaginalis.
Table 3. Sensitivity and Specificity of Discharge and Other Symptoms of Sexually Transmitted Infections (STIs) in Detecting STIs
Laboratory
Diagnosis
Variable Clinical Symptoms + − Sensitivity (%) Specificity (%) PPV (%) NPV (%)
Any discharge-causing STI
(including BV)




+ 25 48 12.3 93.8 34.3 80.2
− 179 723
BV + 44 29 10.0 94.4 59.5 55.9
− 398 504
T. vaginalis + 20 54 13.8 93.5 27.0 86.2
− 125 778
N. gonorrhoeae + 5 68 17.9 92.8 6.9 97.5
− 23 879
C. trachomatis + 5 68 13.9 92.8 6.9 96.6
− 31 871
M. genitalium + 2 72 10.5 92.5 2.7 98.1
− 17 886
HSV-2 (by PCR) + 2 72 8.7 92.5 2.7 97.7
− 21 882
Abbreviations: BV, bacterial vaginosis; C. trachomatis, Chlamydia trachomatis; HSV-2, herpes simplex virus 2; Mycoplasma genitalium, M. genitalium;
N. gonorrhoeae, Neisseria gonorrhoeae; NPV, negative predictive value; PCR, polymerase chain reaction; PPV, positive predictive value; T. vaginalis, Trichomonas
vaginalis.










IL-1β, IL-12p70, TNF-α, TNF-β, RANTES, Flt-3L, VEGF, IL-
2, and IL-17 were significantly elevated in CVL specimens
from women who had vaginal discharge and a laboratory-
diagnosed STI, compared with women who had no STI or
bacterial vaginosis, after adjustment for multiple comparisons
(adjusted P values: .0043, .0016, .0016, .0152, .007, .0064,
.0039, .014, .012, and .0294, respectively). Levels of 7 of these
cytokines (IL-1α, IL-1β, IL-12p70, TNF-α, VEGF, IL-2, and
IL-17), as well as levels of IL-8 and IL-13, were elevated in
women who had ≥1 active STI but no clinical symptoms
(adjusted P values: < .0016, < .0042, .012, .0027, .0429, .0115,
.0204, .0084, and .0462, respectively). Cytokine concentrations
did not differ significantly between women who had asymp-
tomatic STIs and those with symptomatic STIs. It was found
that women who had an STI, either symptomatic or asymp-
tomatic, clustered separately from women who did not have
an STI (Figure 1A). PCA was used to further reduce the com-
plexity of the data set by defining new variables that were
representative of either (1) the unique and common variance
of each of the 42 cytokines assessed or (2) the variance of only
those 12 cytokines that had significantly elevated levels in
CVL from women who had an STI (Figure 1B). It was found
that, although the groups of women were not clearly differen-
tiated using the cluster of 42 cytokines, the estimates of a
component including only the 12 significant cytokines were
significantly higher in women who had either a symptomatic
STI or an asymptomatic infection, compared with women
who did not have an STI. Therefore, women who had asymp-
tomatic STIs had subclinical inflammation that may increase
their susceptibility to HIV infection.
Asymptomatic Laboratory-Diagnosed STIs Were Associated
With Increased Risk of HIV Infection
Of the enrolled 245 HIV-seronegative participants, 28 became
HIV infected, yielding an HIV incidence of 7.2 cases per 100
women-years (95% confidence interval [CI], 4.5–9.8) [38]. As
Figure 1. Cervicovaginal (CVL) cytokine profiles of women who did not have a sexually transmitted infection (STI), compared with women who had
asymptomatic or symptomatic infections. A, Cytokine concentrations were measured in CVL samples that were available for 227 of 242 participants in
this study. Women who did not have an STI, bacterial vaginosis (BV), or vaginal discharge (blue dots/blocks), women who had an asymptomatic STI
(yellow), and women who had a symptomatic STI (orange) were clustered according to their genital cytokine concentrations. Only the cytokines that
differed significantly between these groups after adjustment for multiple comparisons were included in this analysis. Abbreviations: Max, maximum
standardized cytokine concentration measured; Min, minimum standardized cytokine concentration. B, Principal component analysis was used to group
either (1) all cytokines or (2) cytokines that differed significantly between the groups into single components and generate estimates representative of
each component. P values were adjusted for multiple comparisons, using a false discovery rate step-down procedure in order to reduce false-positive
results when multiple comparisons were made. Adjusted (adj.) P values < .05 were considered statistically significant.










3 of these 28 did not have preinfection data, they were
excluded from analysis. Among the STIs tested, N. gonorrhoeae,
C. trachomatis, and M. genitalium were associated with HIV
acquisition (Table 4). After control for demographic and beha-
vioral factors, clinical symptoms, and other STIs, only N.
gonorrhoeae remained significant (adjusted HR, 4.62 [95% CI,
1.34–15.93]). The presence of any STI (excluding bacterial
vaginosis and HSV-2 serology findings) was also significantly
associated with HIV seroconversion (HR, 3.27 [95% CI,
1.49–7.21]). Additionally, the number of STIs was predictive
of HIV infection, with women who had 1 STI having a
3-fold increased risk of acquiring HIV (HR, 2.93 [95% CI,
1.26–6.82]), compared with women with no STI, and those
who had ≥2 concurrent STIs had a 6-fold increased risk of
HIV infection (HR, 6.15 [95% CI, 1.72–22.03]). HSV-2 sero-
positivity, bacterial vaginosis, and vaginal discharge were not
found to increase the risk of HIV acquisition. Genital ulcers
were also not associated with increased risk of HIV infec-
tion, although the prevalence of ulcers was low in this cohort
(n = 3).
Despite the long period between cytokine measurements in
CVL specimens (at enrollment) and HIV infection (median,
302 days prior to infection [range, 14–686 days]), several
inflammatory cytokines were associated with risk of HIV
infection, before adjustment for multiple comparisons. Eleva-
ted concentrations of IL-1β, IL-6, IL-8, and sCD40L were
associated with greater risk of HIV infection (HR [95% CI],
1.25 [1.05–1.50], 1.28 [1.07–1.54], 1.39 [1.04–1.87], and 1.45
[1.02–2.07], respectively, per 1 log10 pg/mL increase in cyto-
kine concentration). Of these cytokines, IL-1β and IL-8 were
elevated in women who had asymptomatic STIs, relative to
women who had no STIs.
DISCUSSION
The prevalence of STIs is generally very high in sub-Saharan
Africa [1, 2], and these infections are associated with increased
susceptibility to HIV acquisition and secondary transmission
[4–11]. There is conflicting evidence regarding the use of syn-
dromic management of STIs for reducing HIV incidence, and
it is thought that this approach may underestimate STI preva-
lence, as many infections are asymptomatic [26–29, 43]. The
prevalence and incidence of laboratory-diagnosed STIs in this
cohort were high; however, only 12.3% of women who tested
positive for ≥1 STI had visible clinical symptoms. As a result,
87.7% of STIs in this cohort of high-risk women would
have been left untreated in a syndromic management setting.
The presence of any laboratory-diagnosed STI was associated
with a 3-fold increased risk of HIV infection, and this associa-
tion was independent of clinical symptoms. The STI most
significantly associated with HIV infection was N. gonor-
rhoeae, increasing the risk of HIV infection by almost 5-fold.
Table 4. Sexually Transmitted Infections (STIs) and Risk of Human Immunodeficiency Virus (HIV) Type 1 Infection
Unadjusted Analysis Adjusted Analysis
Variable HR (95% CI) P HR (95% CI) P
Symptom
Genital ulcers 0 … … …
Discharge 1.04 (.24–4.58) .9594 0.59 (.12–3.00) .5283
Laboratory diagnosis
BV 2.04 (.90–4.63) .0892 1.69 (.71–4.06) .2375
HSV-2 serology 1.30 (.31–5.52) .7234 2.12 (.43–10.50) .3558
HSV-2 (by PCR) 1.96 (.26–14.59) .5108 1.42 (.18–11.44) .7426
T. pallidum 0a … … …
T. vaginalis 1.78 (.71–4.50) .2203 1.74 (.62–4.92) .2935
N. gonorrhoeae 7.74 (2.82–21.24) <.0001 4.62 (1.34–15.93) .0154
C. trachomatis 3.99 (1.19–13.39) .0250 0.90 (.18–4.63) .9006
M. genitalium 4.49 (1.04–19.44) .0446 4.08 (.83–20.19) .0846
Any STI (excluding HSV-2 and BV) 3.27 (1.49–7.21) .0033 … …
No. of concurrent STIs (excluding HSV-2 and BV)
1 2.93 (1.26–6.82) .0124 … …
≥2 6.15 (1.72–22.03) .0053 … …
The multivariate model adjusted for all laboratory-diagnosed STIs and clinical symptoms, as well as for demographic and behavioral factors (data not shown).
Abbreviations: BV, bacterial vaginosis; C. trachomatis, Chlamydia trachomatis; HR, hazard ratio; HSV-2, herpes simplex virus 2; Mycoplasma genitalium,
M. genitalium; N. gonorrhoeae, Neisseria gonorrhoeae; PCR, polymerase chain reaction; T. pallidum, Treponema pallidum; T. vaginalis, Trichomonas vaginalis.
a Participants who tested positive for T. pallidum remained HIV uninfected, and a HR could not be calculated.










No associations were found between abnormal discharge or
genital ulcers and susceptibility to HIV-infection, although
only a small proportion of women presented with ulcers in
this study. Furthermore, HSV-1 was not tested for in this
study but may be considered in future testing algorithms,
given the increasing prevalence of this organism [44]. The
prevalence and incidence of STIs were much higher than the
values of approximately 50% reported in most studies. This
might reflect a higher frequency of reinfection due to the
higher number of partners in this cohort of mainly commer-
cial sex workers.
Genital tract inflammatory cytokine concentrations were
similar in women who had symptomatic and asymptomatic
laboratory-diagnosed STIs and were elevated in these women,
relative to women who had no STIs, bacterial vaginosis, or
symptoms. Previous studies have suggested that elevated
genital tract inflammatory cytokine concentrations may facili-
tate HIV transmission by directly upregulating HIV replica-
tion, by recruiting and activating immune cell targets for HIV
infection, and by disrupting tight junctions between epithelial
cells [31–37]. Although confounded by the long interval
between CVL cytokine measurements and time of HIV infec-
tion and by the fact that women were treated for STIs in the
period between enrollment and the time of HIV infection, we
found that higher concentrations of inflammatory cytokines
(IL-1β, IL-6, IL-8, and sCD40L) in CVL specimens were asso-
ciated with increased risk of HIV infection, albeit weakly. This
supports our finding that women who had no clinical symp-
toms but had subclinical STIs were at increased risk of HIV
acquisition, with N. gonorrhoeae remaining associated after
adjustment for behavioral factors. Although this suggests that
underlying genital tract inflammation may be a biological
mechanism for HIV transmission in these women, it is also
possible that the relationship between elevated inflammation
and risk of HIV infection is indirect. Elevated cytokine concen-
trations were found to be associated with STIs, which may be
markers of high-risk sexual activity and thus increased risk of
HIV infection due to behavior.
The finding that clinically evident and syndromically
managed STIs declined during follow-up while the prevalence
of laboratory-diagnosed STI remained relatively high confirms
that syndromic management does not address subclinical STI
infections, which may contribute to genital inflammation and
risk of HIV infection. This has important implications not
only for HIV prevention strategies, but also for complications
that are associated with untreated inflammatory STIs, includ-
ing pelvic inflammatory diseases, ectopic pregnancy, and in-
fertility [20, 30].
These data create a compelling argument for readdressing
the STI management strategy in high-risk populations in
which negotiating condom use is a challenge for women.
Healthcare systems should include regular screening for STIs
by means of laboratory testing in these groups rather than
relying on symptoms only. The increased diagnostic power of
PCR technology and the related potential to impact the risk of
HIV acquisition could outweigh its high costs. This strategy
would lead to treatment of greater numbers of STIs, reducing
prevalence and incidence. Another diagnostic approach in un-
derresourced areas would be to explore point-of-care STI
testing as an alternative to laboratory testing. Some of these
point-of-care tests have proven to be sensitive diagnostic tools
in trials and would offer significant benefit in both rural and
urban poor-resourced settings that do not have good access to
a larger STI sentinel screening laboratory [45, 46].
Findings from this study and those from studies of other
high-risk cohorts in South Africa [13] suggest that the current
symptom-driven syndromic management system is untenable
for high-risk populations and underscores the need for a para-
digm shift in diagnosing STIs. Only when more effective STI
treatment is achieved are we likely to see STI management
playing a role in HIV prevention.
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